MedTrace Logo

The Pharmacokinetics of GLA5PR Tablet According to the Renal Function

NCT03963362 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-07-23

No results posted yet for this study

Summary

To evauate pharmacokinetics of GLA5PR tablet according to the renal function

Conditions

  • Neuropathic Pain

Interventions

DRUG

GLA5PR tablet 75 mg

GLARS-NF3 tablet

DRUG

GLA5PR tablet 150 mg

GLARS-NF3 tablet

Sponsors & Collaborators

  • GL Pharm Tech Corporation

    lead INDUSTRY

Principal Investigators

  • Minchang Kwon, Ph. D · GL PharmTech Corp.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-17
Primary Completion
2020-12-31
Completion
2021-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03963362 on ClinicalTrials.gov